Latest Growth Strategy News

TPC Consolidated Limited reported a robust 20.9% increase in revenue to $193.1 million for FY25, driven by growth in electricity and gas services. However, net profit after tax plunged 94.4% to $0.3 million, reflecting the impact of volatile wholesale electricity prices and rising costs, while a proposed acquisition awaits regulatory approval.

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Spectur Limited reported a 6% revenue increase to $8.7 million and slashed its net loss by 70% to $779,000 in FY25, driven by operational restructuring and a shift toward recurring revenue streams.

Coventry Group Ltd reported a 1.7% revenue decline and a 40.9% drop in EBITDA for FY25, prompting a major restructuring and a bullish FY26 earnings target above $20 million.

Assetora Limited reports a dramatic 54% reduction in net losses and strengthens its balance sheet, setting the stage for growth with the reopening of the DomaCom Fund.

Assetora Limited reported a reduced loss of $3.35 million for FY2025 despite an 18% revenue decline, focusing on capital raising and fund growth to stabilize operations.

SportsHero Limited reported a 189% revenue increase to AU$37,666 for FY25, driven by strategic partnerships across Southeast Asia, despite a continuing loss of nearly AU$2 million. The company secured major telco collaborations and expanded its gaming product footprint in Indonesia and the Philippines.

Janus Electric Holdings reported a steep 94% rise in net loss to $8.7 million for FY2025, impacted by a disruptive battery recall and significant restructuring costs. The company completed a reverse takeover, raised $8.8 million, and secured a $5 million MOU for African expansion, signaling a bold shift toward heavy transport electrification.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

Aerometrex reported a mixed FY25 with strong MetroMap subscription growth boosting EBITDA despite a decline in LiDAR revenue. The company also appointed Robert Veitch as CEO, signaling a strategic focus on SaaS expansion and diversified geospatial solutions.